Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 26, 2008The Journal of Clinical PharmacologyOpen Access

Pharmacokinetics of Efavirenz When Co‐administered With Rifampin in TB/HIV Co‐infected Patients: Pharmacogenetic Effect ofCYP2B6Variation

View Full Paper
Ask AI
Bookmark
Share

Authors

AKAwewura KwaraUniversity of FloridaMLMargaret LarteyUniversity of GhanaKSKwamena William Coleman SagoeUniversity of Ghana

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Kwara et al. (2008) studied this question.

synapsesocial.com/papers/6a8430d422fbfbf8d78d6bd8https://doi.org/10.1177/0091270008321790
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Multiple-Dose Pharmacokinetics of Efavirenz with and without the Use of Rifampicin in HIV-Positive Patients2007 · 56 citations
  2. 2Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes2004 · 193 citations
  3. 3Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients2005 · 414 citations
  4. 4Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection2003 · 267 citations
  5. 5Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz2006 · 184 citations